Characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), TNBC accounts for 10-20% of all breast cancer cases and has a median overall survival time of less than 18 months in the metastatic setting 2. The gene discussed is ERBB2; the disease is breast carcinoma.